Analyst Price Targets — PTH
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 8, 2026 10:24 am | Martin Auster | Raymond James | $53.00 | $48.46 | StreetInsider | Septerna Inc (SEPN) PT Raised to $53 at Raymond James |
Latest News for PTH
HONG KONG, Aug 31, 2026 - (ACN Newswire) - Operating Cash Flow Turns Positive for the First Time, with a Significantly Strengthened Capital StructureOn August 2
TEL AVIV, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that post-hoc data from its Phase 2 clinical trial of EB613 (oral PTH(1-34) tablet) has been selected for two presentations including the Plenary Poster Presentation at the American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting,…
If you're interested in broad exposure to the Healthcare - Broad segment of the equity market, look no further than the Invesco Dorsey Wright Healthcare Momentum ETF (PTH), a passively managed exchange traded fund launched on October 12, 2006.
EB612, a first-in-class long-acting PTH(1-34) oral peptide for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected in late 2026
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for PTH.
Senate Trading
No Senate trades found for PTH.
U.S. House Trading
No House trades found for PTH.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.